Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Tyler Walburn, Natalie S. Grover, Colette J. Shen, Raghuveer Ranganathan, Christopher Dittus, Anne W. Beaven, Andrew Z. Wang & Kyle Wang. (2021) Consolidative or palliative whole brain radiation for secondary CNS diffuse large B-Cell lymphoma. Leukemia & Lymphoma 62:1, pages 68-75.
Read now
Read now
John N. Allan & Koen Van Besien. (2019) It’s not all about the CNS. High dose methotrexate in DLBCL. Leukemia & Lymphoma 60:8, pages 1845-1847.
Read now
Read now
Hana Malikova, Miroslava Burghardtova, Eva Koubska, Vaclav Mandys, Tomas Kozak & Jiri Weichet. (2018) Secondary central nervous system lymphoma: spectrum of morphological MRI appearances. Neuropsychiatric Disease and Treatment 14, pages 733-740.
Read now
Read now
Danielle H. Oh, Neil Chua, Lesley Street & Douglas A. Stewart. (2016) Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant. Leukemia & Lymphoma 57:1, pages 28-33.
Read now
Read now
Gyeong-Won Lee, Se-Il Go, Seok-Hyun Kim, Junshik Hong, Yu Ri Kim, Sukjoong Oh, Sung-Yong Kim, Young Rok Do, Hyewon Lee, Soon Il Lee, Sung Hwa Bae, Sung Yong Oh, Moo Kon Song, Won-Sik Lee, Bohee Lee, Jin Seok Kim, Min Kyoung Kim, Hye Jin Kang, Jae-Sook Ahn, Ho-Young Yhim, Hyo Jung Kim, Seok Jin Kim, Won Seog Kim & Cheolwon Suh. (2015) Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leukemia & Lymphoma 56:4, pages 1020-1026.
Read now
Read now
Jing Zhang, Bobin Chen & Xiaoping Xu. (2014) Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leukemia & Lymphoma 55:3, pages 509-514.
Read now
Read now
Chan Yoon Cheah & John F. Seymour. (2013) Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma. Leukemia & Lymphoma 54:9, pages 1859-1861.
Read now
Read now
Sushrut Patil, Andrew Spencer, Anthony Schwarer, Sharon Avery, David Ritchie, Stephen Opat, Andrew Wei & Catriona Mclean. (2009) Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Leukemia & Lymphoma 50:12, pages 1964-1968.
Read now
Read now
D. Gholam, F. Bibeau, A. El Weshi, J. Bosq & V. Ribrag. (2003) Primary Breast Lymphoma. Leukemia & Lymphoma 44:7, pages 1173-1178.
Read now
Read now
Rena Buckstein, Wendy Lim, Edmee Franssen & Kevin L. Imrie. (2003) CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature. Leukemia & Lymphoma 44:6, pages 955-962.
Read now
Read now
Articles from other publishers (56)
Michael R. Cook, C. Scott Dorris, Kepher H. Makambi, Yutong Luo, Pashna N. Munshi, Michelle Donato, Scott Rowley, Ayman Saad, Andre Goy, Kieron Dunleavy & Alaa Ali. (2023) Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Advances 7:1, pages 32-39.
Crossref
Crossref
Laura Faiver, Olivia Gutgsell & Yoshie Umemura. 2023. Cerebrospinal Fluid and Subarachnoid Space. Cerebrospinal Fluid and Subarachnoid Space
31
46
.
Fei Xue, Peihao Zheng, Rui Liu, Shaomei Feng, Yuelu Guo, Hui Shi, Haidi Liu, Biping Deng, Teng Xu, Xiaoyan Ke & Kai Hu. (2022) The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. Journal of Oncology 2022, pages 1-20.
Crossref
Crossref
Tiantian Sun, Mi Zhou & Liang Huang. (2022) Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma. Hematology and Oncology Discovery 1:1.
Crossref
Crossref
Mamiko Takahashi, Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiro Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe & Shingen Nakamura. (2021) Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement. The Journal of Medical Investigation 68:1.2, pages 196-201.
Crossref
Crossref
Hanne Kuitunen, Elina Kaprio, Peeter Karihtala, Ville Makkonen, Saila Kauppila, Kirsi-Maria Haapasaari, Milla Kuusisto, Esa Jantunen, Taina Turpeenniemi-Hujanen & Outi Kuittinen. (2020) Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma. Annals of Hematology 99:8, pages 1823-1831.
Crossref
Crossref
Xiaobei Liu, Fei Mo, Hao Zeng, Sha Zhu & Xuelei Ma. (2019) Quantitative proteomic analysis of cerebrospinal fluid from patients with diffuse large B‑cell lymphoma with central nervous system involvement: A novel approach to diagnosis. Biomedical Reports.
Crossref
Crossref
Bhagirathbhai R. Dholaria, Ambuj Kumar, Abdel-Ghani Azzuqua, Taiga Nishihori, Mohamed A. Kharfan-Dabaja, Han W. Tun & Ernesto Ayala. (2019) Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. Clinical Lymphoma Myeloma and Leukemia 19:6, pages e273-e280.
Crossref
Crossref
Sarah J Nagle, Nirav N Shah, Alex Ganetsky, Daniel J Landsburg, Sunita D Nasta, Anthony Mato, Stephen J Schuster, Ran Reshef, Donald E Tsai & Jakub Svoboda. (2017) Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. International Journal of Hematologic Oncology 6:4, pages 113-121.
Crossref
Crossref
Abhimanyu Ghose. (2016) CNS Prophylaxis in Diffuse Large B cell Lymphoma. Journal of Cancer Prevention & Current Research 5:5.
Crossref
Crossref
Megan M. Herr, Nimish A. Mohile, Paul M. Barr, Edwin van Wijngaarden, Edward B. Brown & David Q. Rich. (2016) Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era. Clinical Lymphoma Myeloma and Leukemia 16:9, pages e123-e127.
Crossref
Crossref
Siria A. Lemma, Anna Kaisa Pasanen, Kirsi-Maria Haapasaari, Antti Sippola, Raija Sormunen, Ylermi Soini, Esa Jantunen, Petri Koivunen, Niina Salokorpi, Risto Bloigu, Taina Turpeenniemi-Hujanen & Outi Kuittinen. (2016) Similar chemokine receptor profiles in lymphomas with central nervous system involvement - possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. European Journal of Haematology 96:5, pages 492-501.
Crossref
Crossref
Jennifer BrudnoTamar TadmorStefania Pittaluga, Alina Nicolae, Aaron Polliack & Kieron Dunleavy. (2016) Discordant bone marrow involvement in non-Hodgkin lymphoma. Blood 127:8, pages 965-970.
Crossref
Crossref
C Y Cheah, K E Herbert, K O'Rourke, G A Kennedy, A George, P L Fedele, M Gilbertson, S Y Tan, D S Ritchie, S S Opat, H M Prince, M Dickinson, K Burbury, M Wolf, E H Januszewicz, C S Tam, D A Westerman, D A Carney, S J Harrison & J F Seymour. (2014) A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. British Journal of Cancer 111:6, pages 1072-1079.
Crossref
Crossref
Abhimanyu Ghose, Ria Kundu & Tahir Latif. (2014) Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma. Critical Reviews in Oncology/Hematology 91:3, pages 292-303.
Crossref
Crossref
Y. G. Najjar, K. Mittal, N. N. Faza, H. Dushkin & D. M. Peereboom. (2014) Isolated secondary CNS relapse in a case of stage I diffuse large B-cell lymphoma. Case Reports 2014:may05 1, pages bcr2013201442-bcr2013201442.
Crossref
Crossref
Andrew McMillan, Kirit M. Ardeshna, Kate Cwynarski, Matthew Lyttelton, Pam McKay & Silvia Montoto. (2013) Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. British Journal of Haematology 163:2, pages 168-181.
Crossref
Crossref
Sotirios G. Papageorgiou, Panayiotis Diamantopoulos, Georgia Levidou, Maria K. Angelopoulou, Panagiota Economopoulou, Anna Efthimiou, Nikos Constantinou, Andreas Katsigiannis, Penelope Korkolopoulou, Vassiliki Pappa, Christina Economopoulou, George Georgiou, Maria Dimou, Panagiotis Tsirigotis, Marie‐Christine Kyrtsonis, Ioannis Kotsianidis, Christina Kalpadakis, Meletios‐Athanassios Dimopoulos, Photis Beris, John Meletis, Gerassimos A. Pangalis, John Dervenoulas, Panayiotis Panayiotidis & Theodoros P. Vassilakopoulos. (2012) Isolated central nervous system relapses in primary mediastinal large B‐cell lymphoma after CHOP‐like chemotherapy with or without Rituximab. Hematological Oncology 31:1, pages 10-17.
Crossref
Crossref
Hany R. Guirguis, Matthew C. Cheung, Mervat Mahrous, Eugenia Piliotis, Neil Berinstein, Kevin R. Imrie, Liying Zhang & Rena Buckstein. (2012)
Impact of central nervous system (
CNS
) prophylaxis on the incidence and risk factors for
CNS
relapse in patients with diffuse large
B
‐cell lymphoma treated in the rituximab era: a single centre experience and review of the literature
. British Journal of Haematology 159:1, pages 39-49.
Crossref
Crossref
Noriaki Kawano, Hidenobu Ochiai, Shuro Yoshida, Kiyoshi Yamashita, Kotaro Shide, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Keiko Katayose, Takanori Toyama, Hiroshi Kawano, Hitoshi Matsuoka, Junzo Ishizaki, Koichi Maeda, Seiichi Satou, Tatsuhiko Yano, Kenichiro Yamaguchi, Katsuto Takenaka, Yoshiya Shimao, Koichi Oshima, Akira Ueda & Kazuya Shimoda. (2011) Clinical features and treatment outcomes of isolated secondary central nervous system lymphomas in Miyazaki Prefecture. International Journal of Clinical Oncology 17:4, pages 336-340.
Crossref
Crossref
Tali Siegal & Neta Goldschmidt. (2012) CNS prophylaxis in diffuse large B-cell lymphoma: If, when, how and for whom?. Blood Reviews 26:3, pages 97-106.
Crossref
Crossref
Naoto Tomita, Masahiro Yokoyama, Wataru Yamamoto, Reina Watanabe, Yutaka Shimazu, Yasufumi Masaki, Saburo Tsunoda, Chizuko Hashimoto, Kayoko Murayama, Takahiro Yano, Rumiko Okamoto, Ako Kikuchi, Kazuo Tamura, Kazuya Sato, Kazutaka Sunami, Hirohiko Shibayama, Rishu Takimoto, Rika Ohshima, Yoshihiro Hatta, Yukiyoshi Moriuchi, Tomohiro Kinoshita, Masahide Yamamoto, Ayumi Numata, Yoshiaki Ishigatsubo & Kengo Takeuchi. (2012) Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Science 103:2, pages 245-251.
Crossref
Crossref
Hanny Haaxma-Reiche. 2012. Neuro-Oncology Part II. Neuro-Oncology Part II
711
729
.
Mustafa Khasraw, Ariela Noy, Mark Gilbert & Antonio Omuro. 2012. Lymphoma and Leukemia of the Nervous System. Lymphoma and Leukemia of the Nervous System
267
285
.
Juan-Manuel Sancho, Alberto Orfao, Sandra Quijano, Olga García, Carlos Panizo, Elena Pérez-Ceballos, Guillermo Deben, Antonio Salar, Eva González-Barca, Natalia Alonso, Jose-Antonio García-Vela, Javier Capote, Francisco-Javier Peñalver, Mariano Provencio, Jesús Arias, Josefa Plaza, Dolores Caballero, Marta Morado, Evarist Feliu & Josep-Maria Ribera. (2010) Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin’s lymphoma patients at high risk of central nervous system disease in the rituximab era. European Journal of Haematology 85:4, pages 321-328.
Crossref
Crossref
Pilar Miralles, Juan Berenguer & Josep-Maria Ribera. (2010) Diagnóstico, profilaxis y tratamiento de la afectación del sistema nervioso central por linfoma no hodgkiniano en pacientes con infección por el virus de la inmunodeficiencia humana. Medicina Clínica 135:9, pages 417-422.
Crossref
Crossref
Wataru Yamamoto, Naoto Tomita, Reina Watanabe, Yukako Hattori, Yuki Nakajima, Rie Hyo, Chizuko Hashimoto, Shigeki Motomura & Yoshiaki Ishigatsubo. (2010) Central nervous system involvement in diffuse large B‐cell lymphoma. European Journal of Haematology 85:1, pages 6-10.
Crossref
Crossref
S.J. Kim, S.Y. Oh, J.Y. Hong, M.H. Chang, D.H. Lee, J. Huh, Y.H. Ko, Y.C. Ahn, H.-J. Kim, C. Suh, K. Kim & W.S. Kim. (2010) When do we need central nervous system prophylaxis in patients with extranodal NK/T-cell lymphoma, nasal type?. Annals of Oncology 21:5, pages 1058-1063.
Crossref
Crossref
Michele Spina, Emanuela Chimienti, Ferdinando Martellotta, Emanuela Vaccher, Massimiliano Berretta, Ernesto Zanet, Arben Lleshi, Vincenzo Canzonieri, Pietro Bulian & Umberto Tirelli. (2010) Phase 2 study of intrathecal, long‐acting liposomal cytarabine in the prophylaxis of lymphomatous meningitis in human immunodeficiency virus‐related non‐Hodgkin lymphoma. Cancer 116:6, pages 1495-1501.
Crossref
Crossref
Vittorio Stefoni, Alessandro Broccoli, Cinzia Pellegrini, Enrico Derenzini, Mariapaola Fina & Pier Luigi Zinzani. (2009) CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. Journal of Neuro-Oncology 95:1, pages 135-139.
Crossref
Crossref
Jennifer A. Smith & Michael Glantz. (2009) Statistical and Trial Design Considerations in Central Nervous System Prophylaxis Studies. Seminars in Oncology 36, pages S69-S76.
Crossref
Crossref
Ulrich Herrlinger, Michael Glantz, Uwe Schlegel, Christian Gisselbrecht & Franco Cavalli. (2009) Should Intra-cerebrospinal Fluid Prophylaxis Be Part of Initial Therapy for Patients With Non-Hodgkin Lymphoma: What We Know, and How We Can Find Out More. Seminars in Oncology 36, pages S25-S34.
Crossref
Crossref
Ching-Hon Pui & Eckhard Thiel. (2009) Central Nervous System Disease in Hematologic Malignancies: Historical Perspective and Practical Applications. Seminars in Oncology 36, pages S2-S16.
Crossref
Crossref
Volkmar BoehmeNorbert SchmitzSamira Zeynalova, Markus Loeffler & Michael Pfreundschuh. (2009) CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 113:17, pages 3896-3902.
Crossref
Crossref
Roberto Stasi, Maria Laura Evangelista, Maurizio Brunetti, Stefano Bussa, Raffaele Maritati, Luca Turrini, Silvia Taccogna, Anna Crescenzi & Francesco Angelini. (2008) Analysis of differential therapeutic strategies for primary breast lymphoma: two case reports. Medical Oncology 26:1, pages 22-26.
Crossref
Crossref
Hwee Yong Lim, Eckhard Thiel & Michael J Glantz. (2008) To protect and defend: central nervous system prophylaxis in patients with non-Hodgkinʼs lymphoma. Current Opinion in Oncology 20:5, pages 495-501.
Crossref
Crossref
Nancy D. DoolittleLauren E. AbreyTamara N. ShenkierSiegal TaliJacoline E.C. BrombergEdward A. NeuweltCarole SoussainKristoph JahnkePatrick JohnstonGerald IllerhausDavid SchiffTracy BatchelorSilvia MontotoDale F. Kraemer & Emanuele Zucca. (2008) Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood 111:3, pages 1085-1093.
Crossref
Crossref
B. Gleissner & M. Chamberlain. (2007) Treatment of CNS dissemination in systemic lymphoma. Journal of Neuro-Oncology 84:1, pages 107-117.
Crossref
Crossref
H.-T. Arkenau, G. Chong, D. Cunningham, D. Watkins, R. Agarwal, B. Sirohi, M. Trumper, A. Norman, A. Wotherspoon & A. Horwich. (2007) The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Annals of Oncology 18:3, pages 541-545.
Crossref
Crossref
V. Boehme, S. Zeynalova, M. Kloess, M. Loeffler, U. Kaiser, M. Pfreundschuh & N. Schmitz. (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Annals of Oncology 18:1, pages 149-157.
Crossref
Crossref
Nancy D. Doolittle. 2007. Brain Metastases. Brain Metastases
169
183
.
Quentin A. Hill & Roger G. Owen. (2006) CNS prophylaxis in lymphoma: Who to target and what therapy to use. Blood Reviews 20:6, pages 319-332.
Crossref
Crossref
C. W. Cheung, C. Burton, P. Smith, D. C. Linch, P. J. Hoskin & K. M. Ardeshna. (2005) Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. British Journal of Haematology 131:2, pages 193-200.
Crossref
Crossref
Andrew McMillan. (2005) Central nervous system-directed preventative therapy in adults with lymphoma. British Journal of Haematology 131:1, pages 13-21.
Crossref
Crossref
Silvia Montoto & T. Andrew Lister. (2005) Secondary Central Nervous System Lymphoma: Risk Factors and Prophylaxis. Hematology/Oncology Clinics of North America 19:4, pages 751-763.
Crossref
Crossref
Philip Bierman & Pierre Giglio. (2005) Diagnosis and Treatment of Central Nervous System Involvement in Non-Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America 19:4, pages 597-609.
Crossref
Crossref
G. Spectre, A. Gural, G. Amir, A. Lossos, T. Siegal & O. Paltiel. (2005) Central nervous system involvement in indolent lymphomas. Annals of Oncology 16:3, pages 450-454.
Crossref
Crossref
Jeanine Grier & Tracy Batchelor. (2005) Metastatic neurologic complications of non-Hodgkin’s lymphoma. Current Oncology Reports 7:1, pages 55-60.
Crossref
Crossref
Alexander Lossos, Yaqoub Ashhab, Elena Sverdlin, Gail Amir, Dina Ben‐Yehuda & Tali Siegal. (2004) Late‐delayed cerebral involvement in systemic non‐Hodgkin lymphoma. Cancer 101:8, pages 1843-1849.
Crossref
Crossref
P. Feugier, J.M. Virion, H. Tilly, C. Haioun, G. Marit, M. Macro, D. Bordessoule, C. Recher, M. Blanc, T. Molina, P. Lederlin & B. Coiffier. (2004) Incidence and risk factors for central nervous system occurrencein elderly patients with diffuse large-B-cell lymphoma: influenceof rituximab. Annals of Oncology 15:1, pages 129-133.
Crossref
Crossref
Naoto Tomita, Fumio Kodama, Heiwa Kanamori, Shigeki Motomura & Yoshiaki Ishigatsubo. (2002) Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma. Cancer 95:3, pages 576-580.
Crossref
Crossref
A. Hollender, S. Kvaloy, O. Nome, E. Skovlund, K. Lote & H. Holte. (2002) Central nervous system involvement following diagnosis ofnon-Hodgkin’s lymphoma: a risk model. Annals of Oncology 13:7, pages 1099-1107.
Crossref
Crossref
Richard W Tsang, Mary K Gospodarowicz & Brian O’Sullivan. (2002) Staging and management of localized non-Hodgkin’s lymphomas: variations among experts in radiation oncology. International Journal of Radiation Oncology*Biology*Physics 52:3, pages 643-651.
Crossref
Crossref
Andrew Lister, Lauren E. Abrey & John T. Sandlund. (2002) Central Nervous System Lymphoma. Hematology 2002:1, pages 283-296.
Crossref
Crossref
V. Ribrag, F. Bibeau, A. El Weshi, J. Frayfer, C. Fadel, C. Cebotaru, K. Laribi & P. Fenaux. (2001) Primary breast lymphoma: a report of 20 cases. British Journal of Haematology 115:2, pages 253-256.
Crossref
Crossref
C. Haioun, C. Besson, E. Lepage, C. Thieblemont, D. Simon, C. Rose, H. Tilly, A. Sonet, P. Lederlin, M. Attal, J. Brière & F. Reyes. (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients. Annals of Oncology 11:6, pages 685-690.
Crossref
Crossref